Trial Profile
Traumadornase: a Prospective, Randomized Multicenter, Double Blind Clinical Trial Comparing Inhaled Dornase Alfa and Its Placebo to Reduce the Incidence of Moderate to Severe ARDS in Ventilated Trauma Patients in the Intensive Care Unit
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Dornase alfa (Primary)
- Indications Adult respiratory distress syndrome; Wounds and injuries
- Focus Therapeutic Use
- Acronyms TRAUMADORNASE
- 07 Jul 2022 Planned End Date changed from 1 Sep 2024 to 1 Dec 2024.
- 31 Aug 2021 Planned End Date changed from 1 Nov 2022 to 1 Sep 2024.
- 31 Aug 2021 Planned primary completion date changed from 1 Oct 2022 to 1 Sep 2024.